‍Evidence, outcomes, and insights
‍all in one place

As Ilant Health rapidly expands its value-based care model, the company today announced two senior clinical appointments that build on its success in addressing the broad range of these needs associated with obesity and cardiometabolic health treatment.

The U.S. healthcare system is at a critical juncture with rising obesity and chronic disease coupled with skyrocketing GLP-1 costs. Three in four (76.4%) U.S. adults have at least one chronic condition, and over half (51.4%) have two or more.

In this interview series called “5 Things You Need To Do To Achieve A Healthy Body Weight And Keep It Permanently” we are interviewing health and wellness professionals who can share lessons from their research and experience about how to do this. As a part of this series, I had the pleasure of interviewing Elina Onitskansky.

As more Americans use GLP-1 weight-loss drugs to shrink their waistlines, retail giants are betting on a bottom-line bump tied to a shift in the way the drugs are priced and purchased.

Ilant Health announced that it will offer employers direct contracting and transparent pricing of Eli Lilly and Company (Lilly) obesity management medicines.

Ilant Health, the value-based obesity treatment company working with employers and health plans to deliver clinical outcomes and reduce the total cost of care, announced it has raised $15 million in Series A funding, bringing its total funding to over $22M to date.

Galway Holdings will offer its employees access to Ilant’s comprehensive, evidence-based obesity treatment programs.

The innovative startup has seen continued traction among enterprise leaders and success in tackling obesity and cardiometabolic health issues

Recognition for innovation with awards from EHIR and inclusion in AlphaLab Health’s accelerator.

Ilant Health extended its seed round from $3 million to $5.5 million. The company garnered interest from LifeX Ventures, Celtic House Asia Partners and Cornucopian Capital.

The company initially raised $3 million in seed funding when it launched in October

This decision to extend the seed round comes from Ilant’s accelerating traction due to a solid clinical model and proprietary analytics.

Ilant Health, a leader in value-based obesity management and cardiometabolic health solutions, announced today the extension of its seed round of fundraising from $3 million to $5.5 million